FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3035284598> ?p ?o ?g. }

• W3035284598 abstract "Abstract Current approaches of drugs repurposing against 2019 coronavirus disease (COVID-19) have not proven overwhelmingly successful and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to cause major global mortality. Daclatasvir (DCV) and sofosbuvir (SFV) are clinically approved against hepatitis C virus (HCV), with satisfactory safety profile. DCV and SFV target the HCV enzymes NS5A and NS5B, respectively. NS5A is endowed with pleotropic activities, which overlap with several proteins from SARS-CoV-2. HCV NS5B and SARS-CoV-2 nsp12 are RNA polymerases that share homology in the nucleotide uptake channel. We thus tested whether SARS-COV-2 would be susceptible these anti-HCV drugs. DCV consistently inhibited the production of infectious SARS-CoV-2 in Vero cells, in the hepatoma cell line (HuH-7) and in type II pneumocytes (Calu-3), with potencies of 0.8, 0.6 and 1.1 μM, respectively. Although less potent than DCV, SFV and its nucleoside metabolite inhibited replication in Calu-3 cells. Moreover, SFV/DCV combination (1:0.15 ratio) inhibited SARS-CoV-2 with EC 50 of 0.7:0.1 μM in Calu-3 cells. SFV and DCV prevented virus-induced neuronal apoptosis and release of cytokine storm-related inflammatory mediators, respectively. Both drugs inhibited independent events during RNA synthesis and this was particularly the case for DCV, which also targeted secondary RNA structures in the SARS-CoV-2 genome. Concentrations required for partial DCV in vitro activity are achieved in plasma at Cmax after administration of the approved dose to humans. Doses higher than those approved may ultimately be required, but these data provide a basis to further explore these agents as COVID-19 antiviral candidates." @default.
• W3035284598 created "2020-06-19" @default.
• W3035284598 creator A5000506024 @default.
• W3035284598 creator A5007569728 @default.
• W3035284598 creator A5008262692 @default.
• W3035284598 creator A5010847795 @default.
• W3035284598 creator A5011090397 @default.
• W3035284598 creator A5013169972 @default.
• W3035284598 creator A5015129971 @default.
• W3035284598 creator A5018527455 @default.
• W3035284598 creator A5032988640 @default.
• W3035284598 creator A5033136753 @default.
• W3035284598 creator A5033253153 @default.
• W3035284598 creator A5033987545 @default.
• W3035284598 creator A5035826389 @default.
• W3035284598 creator A5036531858 @default.
• W3035284598 creator A5045550967 @default.
• W3035284598 creator A5047824263 @default.
• W3035284598 creator A5049366282 @default.
• W3035284598 creator A5049963014 @default.
• W3035284598 creator A5050573099 @default.
• W3035284598 creator A5059283340 @default.
• W3035284598 creator A5066429649 @default.
• W3035284598 creator A5074318003 @default.
• W3035284598 creator A5081350037 @default.
• W3035284598 creator A5081931507 @default.
• W3035284598 creator A5085160612 @default.
• W3035284598 creator A5085200610 @default.
• W3035284598 creator A5086545337 @default.
• W3035284598 creator A5087557108 @default.
• W3035284598 creator A5088354512 @default.
• W3035284598 creator A5089439862 @default.
• W3035284598 date "2020-06-16" @default.
• W3035284598 modified "2023-10-18" @default.
• W3035284598 title "The <i>in vitro</i> antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2" @default.
• W3035284598 cites W1979031552 @default.
• W3035284598 cites W2043855224 @default.
• W3035284598 cites W2057441748 @default.
• W3035284598 cites W2113830209 @default.
• W3035284598 cites W2142573506 @default.
• W3035284598 cites W2156321359 @default.
• W3035284598 cites W2177685115 @default.
• W3035284598 cites W2278592283 @default.
• W3035284598 cites W2311770845 @default.
• W3035284598 cites W2410066853 @default.
• W3035284598 cites W2572997664 @default.
• W3035284598 cites W2801148922 @default.
• W3035284598 cites W2903899730 @default.
• W3035284598 cites W2950382369 @default.
• W3035284598 cites W2952023305 @default.
• W3035284598 cites W2952456408 @default.
• W3035284598 cites W2989946545 @default.
• W3035284598 cites W3003899755 @default.
• W3035284598 cites W3008047170 @default.
• W3035284598 cites W3008443627 @default.
• W3035284598 cites W3009885589 @default.
• W3035284598 cites W3012345473 @default.
• W3035284598 cites W3012379316 @default.
• W3035284598 cites W3012652877 @default.
• W3035284598 cites W3013893137 @default.
• W3035284598 cites W3015429854 @default.
• W3035284598 cites W3015554176 @default.
• W3035284598 cites W3015708777 @default.
• W3035284598 cites W3016124786 @default.
• W3035284598 cites W3016771699 @default.
• W3035284598 cites W3018023298 @default.
• W3035284598 cites W3020239101 @default.
• W3035284598 cites W3020896479 @default.
• W3035284598 cites W3023986730 @default.
• W3035284598 cites W3024057275 @default.
• W3035284598 cites W3026711303 @default.
• W3035284598 cites W3027630905 @default.
• W3035284598 cites W3031716590 @default.
• W3035284598 cites W3032677067 @default.
• W3035284598 cites W3036749055 @default.
• W3035284598 cites W3041137986 @default.
• W3035284598 cites W3041968020 @default.
• W3035284598 doi "https://doi.org/10.1101/2020.06.15.153411" @default.
• W3035284598 hasPublicationYear "2020" @default.
• W3035284598 type Work @default.
• W3035284598 sameAs 3035284598 @default.
• W3035284598 citedByCount "20" @default.
• W3035284598 countsByYear W30352845982020 @default.
• W3035284598 countsByYear W30352845982021 @default.
• W3035284598 countsByYear W30352845982022 @default.
• W3035284598 countsByYear W30352845982023 @default.
• W3035284598 crossrefType "posted-content" @default.
• W3035284598 hasAuthorship W3035284598A5000506024 @default.
• W3035284598 hasAuthorship W3035284598A5007569728 @default.
• W3035284598 hasAuthorship W3035284598A5008262692 @default.
• W3035284598 hasAuthorship W3035284598A5010847795 @default.
• W3035284598 hasAuthorship W3035284598A5011090397 @default.
• W3035284598 hasAuthorship W3035284598A5013169972 @default.
• W3035284598 hasAuthorship W3035284598A5015129971 @default.
• W3035284598 hasAuthorship W3035284598A5018527455 @default.
• W3035284598 hasAuthorship W3035284598A5032988640 @default.
• W3035284598 hasAuthorship W3035284598A5033136753 @default.
• W3035284598 hasAuthorship W3035284598A5033253153 @default.
• W3035284598 hasAuthorship W3035284598A5033987545 @default.
• W3035284598 hasAuthorship W3035284598A5035826389 @default.

• next